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Extracorporeal generated shock waves have been introduced for medical therapy 
approximately 20 years ago to disintegrate kidney stones. This was a landmark in the history 
of urinary tract stone therapy. 
During the Second World War it was observed that the lung of castaways was 
cracked because of the explosion of waterbombs, although no outer symptoms of violence 
existed. This was the first time that the influence of shock waves on tissue was observed. 
In 1966 during experiments with high velocity projectiles performed by Dornier Company, 
an employee touched the plate at the very moment where the projectile hit the plate. He felt 
something in his body like an electrical shock. Measurements show that no electricity was 
present. The generated shock wave travelled from the plate, over the hand into the body. 
From 1968 the shock wave effect on biological tissue in animals was investigated in 
Germany, financed by the Department of Defence. These investigations lead to the idea to 
disintegrate kidney stones with extracorporeal generated shock waves. In 1971 Haeusler and 
Kiefer reported about the first in-vitro disintegration of a kidney stone with shock waves 
without direct contact to the stone. In 1974 the Department of Research and Science of 
Germany financed the research program "Application of the ESWL" with participants 
Eisenberger, Chaussy, Brendel, Forßmann and Hepp. In February 1980 the first patient with 
a kidney stone was treated in Munich with a prototype machine called Dornier Lithotripter 
HM1 (Human Model 1).  
In 1983 the first commercial lithotripter (Dornier HM3) was installed in Stuttgart, Germany. 
Today the treatment of kidney and ureteric stones with extracorporeal shock waves is the 
first treatment of choice. More than 10 Million patients have been treated since that.  
The basic mechanism of SWL is that extracorporally generated, focused shock wave 
can fragment urinary calculi into small pieces. The pieces pass along the ureter and voided 
in the urine via the urethra. Shock waves are transported into the body by water. Modern 
lithotripters work without a bathtub and without anaesthesia. For localization of stones, 
lithotripters are equipped with x-ray and/or ultrasound localization systems.  
Shock waves are acoustic waves, characterized by a single high positive pressure 
front and a negative tensile wave afterward. The positive pressure is responsible for the 
direct shock wave effect and the tensile wave for the cavitation, which is called the indirect 
shock wave effect. The very fast pressure transition of shock waves causes very high tension 
at the interfaces (i.e. water – stone) so that the structure of the material cracks.  
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The tensile part of a shock wave corresponds to a local lowering of the pressure so that 
cavitation bubbles will be created; these bubbles are growing under the influence of the 
tensile wave. After a certain time the bubbles collapse uncontrolled. The interaction 
between shock waves and gas bubbles attached to a surface generates water jets and a hole 
will be created on the surface of the stone. The disintegration of a kidney stone is a 
combination between direct and indirect shock wave effect.  
Histological studies in experimental animals and clinical experiences showed that 
ESWL could damage renal tissues and, at least acutely impair renal function. Depending on 
the energy density, first venules are damaged in the medulla, followed by rupture of 
arterioles in the renal cortex. CT and MRI have demonstrated intrarenal and perirenal 
haemorrhage in humans. Determination of urinary enzymes as non-invasive tests of renal 
functional integrity provides a very sensitive indicator of renal damage. The transient 
significant increase in excretion of several urinary enzymes (ASAT, ALAT, NAG, ALP and 
LDH) and low molecular weight proteins such as albumin and β-2 microglobulin following 
ESWL have been well demonstrated in adults, but there are very few clinical data about the 
bioeffect of ESWL in children. Renal impairment after ESWL may be greater in pediatric 
patients than in mature patients determined by anatomical and physiological characteristics 





1. SWL is the first treatment of choice for most urinary calculi in adults. Our aim was to 
review the outcomes of SWL in cases of kidney stones in adult population. We clarified the 
correlations between the stone size and the stone free rate, effectivity and complication rate 
to help on more precise selection of the patient for the treatment. . 
 
2. In children the SWL technique has now been in limited use for more than 10 years. Our 
goal was to prove the clinical safety and efficacy of extracorporeal shock wave lithotripsy in 
pediatric population. Based on our results we determined the optimal treatment settings, 
technical parameters and strategy in childhood. 
 
3. In spite of numerous studies, the biologic effect of ESWL on the immature kidney has not 
yet been evaluated. No data was found in the literature discussing the functional disorders in 
children following SWL. Our goal was to detect the short-term effect of ESWL on renal 
function in children measured by biochemical parameters. The degree and he duration of the 
disorder was discussed.  
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3. EFFICACY OF ESWL TREATMENT FOR UPPER URINARY TRACT STONES 
IN ADULT 
 
3.1. Patients and method 
 
Data of 1070 adult patients treated by ESWL for solitary kidney stone between 1 
February 1993 and 31 December 2000 were analyzed retrospectively. We analyzed the data 
of those patients whose clinical and radiological documentation were available including 
stone analysis and follow-up for at least one year. 1328 treatments were performed for 1070 
stones by Dornier Compact device under ultrasound guidance. After ESWL all patients were 
evaluated at regular intervals (2 week, 1 month, 3 months after treatment and at 6-month 
intervals).  
Patients were divided into two groups based on the stone composition requiring different 
treatment strategies: Group I with Ca containing stones and group II with uric acid (UA) 
containing stones.  
In Group I 1146 ESWL treatments were performed for 926 solitary Ca containing kidney 
stones in three subgroups according to the stone size: smaller than 10 mm, between 10-20 
mm and larger than 10 mm.  
In Group II 199 ESWL treatments were performed for 144 UA containing kidney stone 
patients. The chemical composition was pure (100%) UA in 87 cases and mixed (containing 
at least 60% UA) in 57 cases. After ESWL and between the repeated treatments the 
conventional medication was applied: alkalization of the urine by oral citrate application (to 
pH 6.5-7) and reduction of UA excretion by giving allopurinol (1-3 x 100 mg /day). Stones 
were divided into two subgroups according to the stone size: between 10-20 mm and larger 
than 20 mm.  
Treatments were considered successful, when stones were fragmented and cleared, 
rendering the patient stone-free or with insignificant residual fragments <4 mm.  
We stratified our results according to the stone composition and size. The stone free rates, 
the effectivity quotient (EQ), the retreatment rate, and the auxiliary procedures necessitated 







69% of patients with Ca containing stones smaller then 10 mm became stone free within 
1 month, the ratio increased to 95% after 6 month. In cases of stone size between 10-20 mm, 
the stone free rate was less favourable. Patients with stone larger than 20 mm became stone 
free to six month, but only in 52 %. The ratio of the auxiliary procedures was only 2% in 
subgroup 1, in contradiction to 26% in subgroup 3. Details are shown in the Table.  
 
Stone free Stone size 








<10 mm 613 95 14 3 2 82 
10-20 mm 206 86.6 33 7 7 62 
>20 mm 22 52 116 22 26 23 
Total 841 91 23 5 4 71 
 
Similar relations were observed in Group II. The session number and dissolving time 
correlated with the size of the stone, but even larger pure uric acid stones were dissolved 
successfully using the combined strategy. Mixed stones were partly resistant to combined 
therapy. Direct correlation was detected between treatment failure and the amount of non-
UA stone components. Details are shown in the Table.  
 
Stone free Stone type 









Pure UA 82 94 29 1 5 70 
10-20 mm 57 98.3 20 0 1,7 81 
>20 mm 25 86 45 3 10,3 54.3 
Mixed UA  47 82 52 7 10,5 48.4 
10-20 m 32 86 43 5 8,1 55 
>20 mm 15 75 70 10 15 38.5 






Based on our data, the ESWL treatment seems to be safe, effective and minimally 
invasive in adult patients. Analyzing the treatment results of 1070 solitary kidney stones, the 
total stone free rate was 90.6% and the effectivity quotient was 69.6%. The auxiliary 
procedures rate was favourable - 5%. In patients with Ca containing stone the treatment 
results correlate with the stone size. The stone free rate and the effectivity quotient 
correlated in inverse ratio to stone size. The retreatment rate and number of auxiliary 
procedures increased in direct ratio to the stone size, with a maximum in subgroup of stones 
larger than 20 mm. In the latter case the primary ESWL treatment is not recommended 
because of the low success rate (SF: 57%, EQ: 24%), and the relatively higher complication 
rate (auxiliary procedures rate: 33%).  
Making comparison between the results of the two groups a better outcome (higher 
stone free rate, lower retreatment and complication rate) was observed in Group II 
especially in cases of larger stones. ESWL increases the effectivity of medical therapy, 
because increased surface area of the disintegrated stone comes in touch with alkalinized 
urine. On the other hand, by disintegration of stone, inside UA layers became accessible for 
dissolving agents, resulting in better dissolving effect, shorter dissolving time and low 
complication rate.  
 
 
4. APPLICATION OF SHOCK WAVE LITHOTRIPSY IN PEDIATRIC 
POPULATION 
 
4.1. Patients and method 
 
Between February 1993 and December 2005, 104 children with 129 urinary stones 
(95 renal, 34 ureteric stone) were treated with the second generation Dornier Compact 
lithotripter. There were 55 boys 49 girls with a mean age of 10.3 (4–l6) years.  
Treatments were given under ultrasound guidance in 139 SWL sessions for 95 renal, 
8 upper ureteric, 3 middle ureteric and 23 lower ureteric stones. 
The mean stone size was 11.4 mm (4.8–22.5 mm). The number of shock waves per 
stone averaged 2510 (1489-3200). The mean size of ureteric stones was 12.1 mm, the 
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average shock wave number was 2830 (2500–3500). Shock wave energy settings ranged 
from 11 to 13 kV. Treatments were considered successful, when stones were fragmented 
and cleared, rendering the patient stone-free or with insignificant residual fragments < 3 
mm.  
The stone free rate, the efficacy quotient and the complication rate was calculated. 
The history of the patients, the stone composition and the stone recurrence was analyzed 




The overall stone-free rate was (91.5 %) and the efficiency quotient (EQ) was 82.5 % at 3 
months after SWL. The complication rate was favourable - 3.1 %. Results are summarized 
in Table.   
 
 Kidney Ureter Total 
No stones 95 34 129 
No stone free 86 32 118 
No retreatment 7 3 10 
Residual fragment >3 mm 7 0 7 
Auxiliary procedures 0 0 0 
Secondary operation  2 PCNL 2 URS 4 
EQ (%) 82.6 82 82.5 
 
Documented stone forming risk factor was fond in 44 patients (42.3%): metabolic 
disorder was found in 30 patients (hypercalciuria, hypomagnesiuria, cystinuria), anatomic 
alteration in 13 patients, infect origin in 6 cases, familiar in 5 cases.  
Stone analysis was performed in 80 patients. The result was: Ca oxalate dihydrate 
alone in 59% and Ca oxalate dihydrate in combination with monohydrate in 19%, struvit in 
5 % and cystine in 4 % of the cases. The stone recurrence rate was 14 %. 
 
4.3. Conclusions  
 
ESWL in children requires special technical adaptation and modifications of 
treatment. The treatment should be effective but protective. The technical parameters of 
each ESWL machines are very different, but second or third generation, ultrasound guided 
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machines with small focal zone are recommended for the treatment. 
Technically, the flat table of the device permitted easier positioning. The small focal 
zone is optimal to minimize the injuries of surrounding organs. In our practice there was no 
need for lung shielding.  
According to our experience, the real-time monitoring via ultrasound during the 
treatment enabled prompt correction of positioning and resulted in a decrease in retreatment 
rate and in shock numbers. On the other hand, by using ultrasound guidance, the radiation 
exposure could be removed. More precise focusing results in less parenchyma injury.   
Experienced urologist must perform the treatment. The power setting and shock 
wave number should be kept to as low as possible but high enough to reach optimal 
disintegration. In childhood the calcium oxalate dihydrate stones are the most common, 
which disintegrate at lower energy. 
Stone fragments passed faster and with fewer complications in children than in 
adults. On the other hand, children had a better stone clearance rate than adults at the same 
interval due to shorter stone lodge, more rapid and better mobilization after treatment.   
In our series the overall success rate was favourable. The retreatment rate is lower 
than those reported in other paediatrics series. The complication rate and secondary 
operation number was low, but endoscopic background and experiences operator was 
mandatory. In conclusion, SWL using ultrasound guided Dornier Compact lithotripter is an 
effective treatment of most urinary stones in children. Because of the high success rate and 
the low risk of complications, lithotripsy can be applied as an outpatient treatment modality 
in children over 4 years of age. In nearly half of the cases a predisposing factor for stone 
formation can be found in children, and the stone recurrence rate is higher than in adult 
population. Detailed physical and laboratory examinations, analysis of the calculus can help 
to evaluate the causes. Regular follow-up and preventive medical therapy is required.  
 
 
5. SHORT –TERM CHANGES IN RENAL FUNCTION FOLLOWING ESWL IN 
CHILDREN 
 
5.1. Patients and method 
 
In 16 children (8 boys, 8 girls) aged 6-12 (mean 9.6 years) treated at our department, 
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the short-term effect of ESWL was studied measuring changes of biochemical markers in a 
12-month period. The children were treated for single kidney stones in the first session 
under general anaesthesia. The mean stone size was 8.2 mm (range 6 –12), 9 stones were on 
the left side, 7 on the right side. Treatments were done under continuous real-time US 
monitoring controlled by the same urologist. The number of shock waves per stone 
averaged 2360 (1420–2700). Shock wave energy settings ranged from 11 kV to 13 kV. 
Children with concomitant diseases, urogenital tract abnormalities and previous operation 
on the urogenital tract or uroinfection were excluded from the study. 
Over the routine follow-up procedures excretion of electrolytes (Na, K, urea, 
creatinine), β-2 microglobulin and urinary activities of ASAT, ALAT, ALP, LDH were 
checked as well as different serum parameters (Na, K, urea, creatinine levels). Serum C-
reactive protein (CRP) was determined to detect acute infection.  
Samples were collected immediately before and 2 hours after ESWL, and on days 1, 2, 8, 
15, 30 and 90 following the treatment. 
Urinary enzyme levels were reported in relation to urinary creatinine concentration. The 
results were expressed as mean +/- standard error of mean. Pre-treatment levels were 
considered as a baseline. Statistical analysis of data was made by paired t-test. P values less 




The overall renal function (serum Na, K, urea, creatinine levels) and urinary excretion of 
electrolytes remained stable. CRP remained within the normal range excluding urinary and 
non-urinary infections. 
The excretion of ALAT remained unaltered. A mild elevation of ASAT (p <0.01) 
excretion was detected after the ESWL, returning to the baseline level to the 7th day. 
ALP was increased at a five-fold level relative to baseline immediately after the treatment 
(p<0.01), and stayed elevated until the 7th day. The LDH excretion increased extremely, 
more than twenty-fold (p <0.001) relative to pre-treatment value 2 hours after the ESWL, it 
remained high on first day, then showed a rapid decrease to 7th day. Pre-treatment value was 





A marked increase of albumin and β-2 microglobulin level occurred 2 hours after the 
treatment (p <0.001) and on first day (p <0.01). On the seventh day, only a mild but 
significant elevation was found (p<0.02), and the excretion decreased to the baseline level 





Theoretically the higher water content of immature tissues can result in increased 
possibility of cavitation and jet effect and better shock wave extension into soft tissues. The 
smaller size of organs can result in wider propagation of shock wave energy existing as a 












be ta-2 m icroglobulin album in





















ESWL                                                                
 27
be more susceptible for SW hazard.   
Macroscopic alterations of the treated region (haematoma of the kidney or 
neighbouring organs) were not observed at our series, and the overall renal function 
remained stable.  
Urinary loss of different enzymes and proteins was detected following ESWL, 
originated from transient disorder of the kidney. No previous data have been found in the 
literature studying functional changes of renal function in children. Our study documents a 
transient renal proximal tubular dysfunction in children.  
A mild and short-duration elevation of the cytoplasmic enzyme ASAT was found. 
No difference was detected according to the sex and side. No change was observed in 
urinary levels of ALAT of mitochondrial origin. These data correlate with ultrastructural 
findings showing vacuolization of cytoplasm and disruption of cell membranes. 
Mitochondria seem to be more resistant to SW energy. 
The dramatically elevated LDH level in urine denotes cellular damage of the kidney and 
surrounding muscles as well. In comparison with girls, a more prominent elevation of LDH 
was detected in boys whose musculature is generally stronger. It is known that 10-20 % of 
SW energy is lost through the skeletal muscles. 
The increase of the brush border enzyme ALP is an indicator of proximal tubular 
dysfunction. The elevation of it was detectable at least two weeks after treatment as well as 
β-2 microglobulin. 
Post-treatment elevation of albumin and β-2 microglobulin was described in several 
studies, but enhancement of albumin excretion is partially due to haematuria after the 
treatment. The β-2 microglobulin normally freely filtered glomerularly and almost 
completely reabsorbed in the proximal tubule. The elevated β-2 microglobulin levels in 
urine samples after ESWL indicate incomplete reabsorption which can result from either a 
functional alteration of proximal tubular permeability or more likely a direct mechanical 
effects, namely membrane rupture which regenerates within two weeks.  
The longer regeneration time of tubular function in children in comparison to adults (14 
days versus 7 days) shows that ESWL can be more detrimental on growing organs. To 
reduce the possibility of more serious or prolonged functional disorders, we suggest waiting 





1. ESWL is the primary treatment option for most urinary stones. Analyzing the treatment 
results of 1070 solitary kidney stones, the total stone free rate was 90.6% and the 
effectivity quotient was 69.6%. The auxiliary procedures rate was favourable - 5 %.  
 
2. The stone free rate and the effectivity quotient correlated in inverse ratio to stone size. 
The retreatment rate and number of auxiliary procedure increased in direct ratio to the 
stone size, with a maximum in subgroup of stones larger than 20 mm.  
 
3. In this cases of stones larger than 20 mm the primary ESWL treatment is not 
recommended because of the low success rate (SF: 57 %, EQ: 24%), and the relatively 
higher complication rate (auxiliary procedures rate: 33%).  
 
4. Even larger pure uric acid stones were dissolved using combined (ESWL + dissolving 
therapy) treatment. The session number and the dissolving time correlated with the size 
of the stone. ESWL improved the effectivity of medical therapy, because increased 
surface area of the disintegrated stone comes in touch with alkalinized urine. 
 
5. SWL using ultrasound guided Dornier Compact lithotripter is an effective treatment for 
most urinary tract stones in children. Based on the treatment result of 104 children (4-16 
age), the overall stone-free rate was (91.5 %) and the efficiency quotient (EQ) was 82.5 
% The complication rate was favourable - 3.1 %.  
 
6. The special technical adaptation and modifications required for effective but protective 
SWL treatment of children are discussed. The conditions of optimal treatment are: : 
• machine related (small focal zone, US imaging) 
• patient related (age, stone size, position and composition) 
• operator related (adequate treatment strategy including limitation of power setting 
and shock wave number, experience, endoscopic background, follow-up). 
 
7. Documented stone forming risk factors were fond in 44 patients (42.3%): metabolic 
disorder was found in one third of the patients, anatomic alteration in one quarter of 
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patients, infect origin and familiar causes in 10%. Stone analysis was performed in 80 
patients. The stone recurrence rate was 14 % despite of adequate prophylactic treatment. 
 
8. No data was found in the literature discussing the functional disorders in children 
following SWL. Analyzing different urinary enzyme leakage and albumin and β-2 
microglobulin levels in the urine I documented a transient renal proximal tubular 
dysfunction in children following SWL. The data indicates either a functional alteration 
of proximal tubular permeability or more likely direct mechanical effects, namely 
membrane rupture which regenerates within two weeks.  
 
9. The longer regeneration time of tubular function in children in comparison to adults (14 
days versus 7 days) shows that ESWL can be more detrimental on growing organs. 
Considering the functional regeneration time, we suggest to wait minimally 14 days 
before repeated ESWL or other operation  
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